dc.creator | Fernandez Rivera, Constantino | es |
dc.creator | Calvo Rodríguez, María | es |
dc.creator | Poveda, José Luís | es |
dc.creator | Crespo, Marta | es |
dc.creator | Gomez, Gonzalo | es |
dc.creator | Cabello Pelegrin, Sheila | es |
dc.creator | Fernández Rodríguez, Ana | es |
dc.creator | Hernandez, Domingo | es |
dc.date.accessioned | 2022-11-24T14:42:11Z | |
dc.date.available | 2022-11-24T14:42:11Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Fernandez Rivera, C., Calvo Rodríguez, M., Poveda, J.L., Crespo, M., Gomez, G., Cabello Pelegrin, S.,...,Hernandez, D. (2022). Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study. Clinical Transplantation, 36 (3), e14550. https://doi.org/10.1111/ctr.14550. | |
dc.identifier.issn | 0902-0063 | es |
dc.identifier.issn | 1399-0012 | es |
dc.identifier.uri | https://hdl.handle.net/11441/139755 | |
dc.description.abstract | Multicenter, prospective, observational study to compare the relative bioavailability of
once-daily tacrolimus formulations in de novo kidney transplant recipients. De novo
kidney transplant recipients who started a tacrolimus-based regimen were included
14 days post-transplant and followed up for 6 months. Data from 218 participants were evaluated: 129 in the LCPT group (Envarsus) and 89 in the PR-Tac (Advagraf) group.
Patients in the LCPT group exhibited higher relative bioavailability (Cmin /total daily
dose [TDD]) vs. PR-Tac (61% increase; P < .001) with similar Cmin and 30% lower TDD
levels (P < .0001). The incidence of treatment failure was 3.9% in the LCPT group and
9.0% in the PR-Tac group (P = .117). Study discontinuation rates were 6.2% in the LCPT
group and 12.4% in the PR-Tac group (P = .113). Adverse events, renal function and
other complications were comparable between groups. The median accumulated dose
of tacrolimus in the LCPT group from day 14 to month 6 was 889 mg. Compared to
PR-Tac, LCPT showed higher relative bioavailability, similar effectiveness at preventing
allograft rejection, comparable effect on renal function, safety, adherence, treatment
failure and premature discontinuation rates. | es |
dc.format | application/pdf | es |
dc.format.extent | 12 p. | es |
dc.language.iso | eng | es |
dc.publisher | Wiley-Blackwell | es |
dc.relation.ispartof | Clinical Transplantation, 36 (3), e14550. | |
dc.rights | Atribución-NoComercial 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | * |
dc.subject | Bioavailability | es |
dc.subject | Clinical practice | es |
dc.subject | Pharmacokinetics | es |
dc.subject | Renal transplantation | es |
dc.subject | Tacrolimus | es |
dc.subject | Treatment failure | es |
dc.title | Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Citología e Histología Normal y Patológica | es |
dc.relation.publisherversion | https://onlinelibrary.wiley.com/doi/10.1111/ctr.14550 | es |
dc.identifier.doi | 10.1111/ctr.14550 | es |
dc.contributor.group | Universidad de Sevilla. CTS949: Biopatología y estrés oxidativo. | es |
dc.journaltitle | Clinical Transplantation | es |
dc.publication.volumen | 36 | es |
dc.publication.issue | 3 | es |
dc.publication.initialPage | e14550 | es |